InvestorsHub Logo
Followers 234
Posts 26887
Boards Moderated 0
Alias Born 01/12/2013

Re: biowreck post# 121623

Monday, 01/29/2018 8:33:04 AM

Monday, January 29, 2018 8:33:04 AM

Post# of 426487
Janet Woodcock stated Vascepa should take DS route, and this is how CDER views the $250 million Amarin has spent on R-I clinical trial. It further adds injury to the insult of October 16th Ad Com which slandered R-I with mineral oil and foreshadowed the agencies intent to rescind ANCHOR creating the possibility of R-I rescindment. This destroyed the stock in case you haven't been paying attention.

BB

Mr. McGee, don't make me angry. You wouldn't like me when I'm angry---David Banner

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News